Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein

Summary

Beyond their primary role in haemostasis and tissue repair, platelets are causally involved in the onset of inflammatory reactions, cell proliferation and immune response. Platelet activation and platelet binding to the endothelium result in release of chemokines and increased expression of adhesion molecules, which promote the recruitment of leukocytes that will eventually migrate across the endothelium into the tissue. Here, we provide the first evidence that platelets stimulated with oxidised low-density lipoprotein (oxLDL) directly enhance recruitment and transmigration of neutrophils, via cell-cell interaction. OxLDL immediately activates platelets, which then rapidly bind to neutrophils, foster their activation and facilitate transmigration through an endothelial monolayer. The observed effects of oxLDL on platelet-neutrophil aggregate (PNA) formation depend on incubation time, lipoprotein concentration and the degree of oxidative modification of LDL. PNA form within minutes following stimulation by oxLDL and remain for up to 1 h post stimulation, while native LDL is unable to induce platelet-neutrophil interactions. In the presence of acetylsalicylic acid the formation of PNA in response to oxLDL is virtually absent, and platelets fail to further enhance oxLDL-induced neutrophil transmigration. P2Y₁ and P2Y₁₂ inhibitors have less pronounced effects on PNA formation in response to oxLDL. Furthermore, we demonstrate that the PI3K pathway is essential for efficient neutrophil transmigration induced by oxLDL. Consequently, platelets enhance neutrophil transmigration in response to oxLDL and might thereby contribute essentially to the amplification of inflammatory processes within the vessel wall, which fosters the development of atherosclerosis.

Keywords

Neutrophil recruitment - platelet immunology - oxidised LDL - Pselectin

• References

• 1 Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
• 2 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131-2137.
• 3 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 4 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
• 5 Massberg S, Brand K, Gruner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
• 6 Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
• 7 Diacovo TG, Roth SJ, Buccola JM. et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-157.
• 8 Larsen E, Celi A, Gilbert GE. et al. PAD GEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 1989; 59: 305-312.
• 9 Linden MD, Furman MI, Frelinger III AL. et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007; 05: 761-765.
• 10 Lievens D, Zernecke A, Seijkens T. et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
• 11 Drechsler M, Megens RT, van Zandvoort M. et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-1845.
• 12 Furman MI, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-1006.
• 13 Lam FW, Burns AR, Smith CW. et al. Platelets enhance neutrophil transendothelial migration via P-selectin glycoprotein ligand-1. Am J Physiol Heart Circ Physiol 2011; 300: H468-H475.
• 14 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 15 van der Wal AC, Becker AE. Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability. Cardiovasc Res 1999; 41: 334-344.
• 16 Steinberg D, Parthasarathy S, Carew TE. et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
• 17 Avogaro P, Bittolo BG, Cazzolato G. Isolation and partial characterization of an oxidized LDL in humans. Basic Life Sci 1988; 49: 391-396.
• 18 Harats D, Ben-Naim M, Dabach Y. et al. Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis 1990; 85: 47-54.
• 19 Lehr HA, Hubner C, Finckh B. et al. Role of leukotrienes in leukocyte adhesion following systemic administration of oxidatively modified human low density lipoprotein in hamsters. J Clin Invest 1991; 88: 9-14.
• 20 Lehr HA, Olofsson AM, Carew TE. et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994; 71: 380-386.
• 21 Quinn MT, Parthasarathy S, Fong LG. et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-2998.
• 22 Siegel-Axel D, Daub K, Seizer P. et al. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res 2008; 78: 8-17.
• 23 Assinger A, Koller F, Schmid W. et al. Hypochlorite-oxidized LDL induces intra-platelet ROS formation and surface exposure of CD40L--a prominent role of CD36. Atherosclerosis 2010; 213: 129-134.
• 24 Assinger A, Laky M, Schabbauer G. et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost 2011; 09: 799-809.
• 25 Butler LM, Jeffery HC, Wheat RL. et al. Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasion. J Virol 2011; 85: 7321-7332.
• 26 Volf I, Roth A, Cooper J. et al. Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL. FEBS Lett 2000; 483: 155-159.
• 27 Arnhold J, Wiegel D, Richter O. et al. Modification of low density lipoproteins by sodium hypochlorite. Biomed Biochim Acta 1991; 50: 967-973.
• 28 Moore Jr JE, Xu C, Glagov S. et al. Fluid wall shear stress measurements in a model of the human abdominal aorta: oscillatory behavior and relationship to atherosclerosis. Atherosclerosis 1994; 110: 225-240.
• 29 Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012; 110: 875-888.
• 30 Mayadas TN, Johnson RC, Rayburn H. et al. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74: 541-554.
• 31 Pitchford SC, Momi S, Giannini S. et al. Platelet P-selectin i s required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood 2005; 105: 2074-2081.
• 32 van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85: 195-204.
• 33 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 09: 61-67.
• 34 Lukasik M, Dworacki G, Michalak S. et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. Thromb Res 2011; 128: e73-e80.
• 35 Boncler M, Gresner P, Nocun M. et al. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta 2007; 1770: 1651-1659.
• 36 Furuno T, Yamasaki F, Yokoyama T. et al. Effects of various doses of aspirin on platelet activity and endothelial function. Heart Vessels 2011; 26: 267-273.
• 37 Haseruck N, Erl W, Pandey D. et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 2004; 103: 2585-2592.
• 38 Li N, Hu H, Hjemdahl P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.
• 39 Fierro IM, Colgan SP, Bernasconi G. et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J Immunol 2003; 170: 2688-2694.
• 40 Pitchford SC. Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol 2007; 152: 987-1002.
• 41 Leon C, Ravanat C, Freund M. et al. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23: 1941-1947.
• 42 Leon C, Alex M, Klocke A. et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2004; 103: 594-600.
• 43 Nakhaei-Nejad M, Hussain AM, Zhang QX. et al. Endothelial PI 3-kinase activity regulates lymphocyte diapedesis. Am J Physiol Heart Circ Physiol 2007; 293: H3608-H3616.